A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

BELLEVUE, Wash., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Truveta announced today that Truveta Data, the most complete, timely, and clean electronic health record (EHR) data, now includes more than 120 ...

2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...

Artemis Bayandor from Illinois in the US lost over a stone after starting to take game-changing weight-loss jabs, but like ...

A new study found bariatric surgeries have recently dropped as the popularity of weight-loss drugs like Wegovy and Ozempic ...

Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual ...

With new weight-loss drugs hailed as ‘miracle’ medicines, Harriet Symonds explores whether their increasing popularity should ...

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...

In our country, 4 out of 10 adults are overweight, and slightly more than 1 in 10 live with a condition of obesity, a chronic ...